

GFPT1 Polyclonal Antibody

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP55140

Specification

GFPT1 Polyclonal Antibody - Product Information

Buffer0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.SIMILARITYContains 1 glutamine amidotransferase type-2 domain. Contains 2 SIS domains.SUBUNIT DISEASEDefects in GFPT1 are the cause of limb-girdle myasthenia with tubular aggregates (LGMTA) [MIM:610542]. A congenital myasthenic syndrome characterized by onset of proximal muscle weakness in the first decade. Individuals with this condition have a recognizable pattern of weakness of shoulder and pelvic girdle muscles, and sparing of ocular or facial muscles. EMG classically shows a decremental response to repeated nerve stimulation, a sign of neuromuscular junction dysfunction. Affected individuals show a favorable response to acetylcholinesterase (AChE) inhibitors.Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.	Application Primary Accession Reactivity Host Clonality Calculated MW Physical State Immunogen Epitope Specificity Isotype Purity affinity purified by Protein A	WB, IHC-P, IHC-F, IF, ICC, E <u>Q06210</u> Rat, Pig, Dog Rabbit Polyclonal 79 KDa Liquid KLH conjugated synthetic peptide derived from human GFPT1 601-699/699 IgG
SIMILARITYProclin300 and 50% Glycerol. Contains 1 glutamine amidotransferase type-2 domain. Contains 2 SIS domains. HomotetramerDISEASEDefects in GFPT1 are the cause of limb-girdle myasthenia with tubular aggregates (LGMTA) [MIM:610542]. A congenital myasthenic syndrome characterized by onset of proximal muscle weakness in the first decade. Individuals with this condition have a recognizable pattern of weakness of shoulder and pelvic girdle muscles, and sparing of ocular or facial muscles. EMG classically shows a decremental response to repeated nerve stimulation, a sign of neuromuscular junction dysfunction. Affected individuals show a favorable response to acetylcholinesterase (ACHE) inhibitors.Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.	Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02%
SUBUNIT DISEASEtype-2 domain. Contains 2 SIS domains. Homotetramer Defects in GFPT1 are the cause of limb-girdle myasthenia with tubular aggregates (LGMTA) [MIM:610542]. A congenital myasthenic syndrome 		Proclin300 and 50% Glycerol.
DISEASE Defects in GFPT1 are the cause of limb-girdle myasthenia with tubular aggregates (LGMTA) [MIM:610542]. A congenital myasthenic syndrome characterized by onset of proximal muscle weakness in the first decade. Individuals with this condition have a recognizable pattern of weakness of shoulder and pelvic girdle muscles, and sparing of ocular or facial muscles. EMG classically shows a decremental response to repeated nerve stimulation, a sign of neuromuscular junction dysfunction. Affected individuals show a favorable response to acetylcholinesterase (AChE) inhibitors. This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.	SIMILARIT	
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.		Defects in GFPT1 are the cause of limb-girdle myasthenia with tubular aggregates (LGMTA) [MIM:610542]. A congenital myasthenic syndrome characterized by onset of proximal muscle weakness in the first decade. Individuals with this condition have a recognizable pattern of weakness of shoulder and pelvic girdle muscles, and sparing of ocular or facial muscles. EMG classically shows a decremental response to repeated nerve stimulation, a sign of neuromuscular junction dysfunction. Affected individuals show a favorable response to
		This product as supplied is intended for research use only, not for use in human,

Background Descriptions

Glutamine:fructose-6-phosphate amidotransferase (GFAT1) is the first and rate-limiting enzyme for the entry of glucose into the hexosamine biosynthesis pathway (HBP) in mammals. GFAT1, a member of the N-terminal nucleophile class of amidotransferases, converts fructose-6-phosphate into N-acetylglucosamine-6-phosphate. Hyperglycemia-induced insulin resistance, a condition in which exposure to high concentrations of glucose and insulin results in insulin resistance, may result from increased glucose metabolism through the HBP. Hyperglycemia-induced insulin resistance is a characteristic feature of type 2 diabetes. Consequently, GFAT1 is a potential



therapeutic target in the treatment of type 2 diabetes.

GFPT1 Polyclonal Antibody - Additional Information

Gene ID 2673

Other Names Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1, 2.6.1.16, D-fructose-6-phosphate amidotransferase 1, Glutamine:fructose-6-phosphate amidotransferase 1, GFAT 1, GFAT1, Hexosephosphate aminotransferase 1, GFPT1, GFAT, GFPT

Target/Specificity

Isoform 1 is predominantly expressed in skeletal muscle. Not expressed in brain. Seems to be selectively expressed in striated muscle.

Dilution

WB~~1:1000<br \>IHC-P~~N/A<br \>IHC-P~~N/A<br \>IF~~1:50~200<br \>ICC~~N/A<br \>ICC~~N/A<br \>ICC~~N/A</spa

Format

0.01M TBS(pH7.4), 0.09% (W/V) sodium azide and 50% Glyce

Storage

Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

GFPT1 Polyclonal Antibody - Protein Information

Name GFPT1

Synonyms GFAT, GFPT

Function

Controls the flux of glucose into the hexosamine pathway. Most likely involved in regulating the availability of precursors for N- and O-linked glycosylation of proteins. Regulates the circadian expression of clock genes BMAL1 and CRY1 (By similarity). Has a role in fine tuning the metabolic fluctuations of cytosolic UDP-GlcNAc and its effects on hyaluronan synthesis that occur during tissue remodeling (PubMed:>26887390).

Tissue Location

Isoform 1 is predominantly expressed in skeletal muscle. Not expressed in brain. Seems to be selectively expressed in striated muscle.

GFPT1 Polyclonal Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.



- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

GFPT1 Polyclonal Antibody - Images



Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;

Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min;

Incubation: Anti-GFPT1 Polyclonal Antibody, Unconjugated(bs-13341R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining